Activity | Phase(time points) | Screening stage | baseline period | intervention | Follow-up | |
---|---|---|---|---|---|---|
−3d~0d | 0d | 4w | 8w | 12w | ||
Enrolment | Sign informed consent | ✔ | ||||
Inclusion and exclusion criteria | ✔ | |||||
Demographic data | ✔ | |||||
Medical history and treatment history | ✔ | |||||
Basic data collection | ✔ | |||||
Outcome assessment | Frequency of atrial fibrillation | ✔ | ✔ | ✔ | ✔ | |
ECG and Holter | ✔ | ✔ | ✔ | ✔ | ||
Ultrasonic cardiogram | ✔ | ✔ | ✔ | ✔ | ||
TCM clinical syndrome integral | ✔ | ✔ | ✔ | ✔ | ||
Rate of increase and decrease of anti-arrhythmia western medicine | ✔ | ✔ | ✔ | ✔ | ||
NT-proBNP | ✔ | ✔ | ||||
Hamilton Anxiety Scale | ✔ | ✔ | ✔ | ✔ | ||
Hamilton Depression Scale | ✔ | ✔ | ✔ | ✔ | ||
SF-36 | ✔ | ✔ | ✔ | ✔ | ||
PVO | ✔ | ✔ | ✔ | ✔ | ||
Anaerobic threshold | ✔ | ✔ | ✔ | ✔ | ||
Safety assessment | Physical examination | ✔ | ✔ | ✔ | ✔ | |
Blood routine examination | ✔ | ✔ | ||||
Urine routine and urinary sediment | ✔ | ✔ | ||||
Liver function | ✔ | ✔ | ||||
Renal function | ✔ | ✔ | ||||
Blood lipid | ✔ | ✔ | ||||
GLU | ✔ | ✔ | ||||
INR | ✔ | ✔ | ||||
CHA2DS2-VAS | ✔ | ✔ | ||||
HAS-BCED | ✔ | ✔ | ||||
Other information | Randomization | ✔ | ||||
Hemorrhage | ✔ | ✔ | ✔ | ✔ | ||
Readmission | ✔ | ✔ | ✔ | ✔ |